Palvella Therapeutics Inc (NASDAQ: PVLA) is a late clinical-stage biopharmaceutical company developing drug candidates for rare skin diseases. The company has generated no revenue from product sales as of the fiscal year ended December 31, 2025, and funds operations through external financing rather than commercial activity. Its lead program, QTORIN rapamycin, targets rare dermatological indications, and a second candidate, QTORIN pitavastatin, is in IND-enabling development for disseminated superficial actinic porokeratosis (DSAP). Palvella entered a development funding agreement with Ligand Pharmaceuticals, under which Ligand provided an upfront payment in exchange for tiered future royalties on any worldwide net product sales of QTORIN rapamycin-based products. The royalty agreement liability carried a balance sheet value of $11.9 million as of December 31, 2025, with imputed interest expense of $3.9 million recognized for the year ended December 31, 2025. The company has no approved products and has not yet conducted commercial-scale manufacturing or sales activities.

Revenue model

No product revenue as of December 31, 2025. Operations are funded through external financing. A development funding agreement with Ligand Pharmaceuticals provided an upfront payment; in return, Palvella owes Ligand tiered royalties on future worldwide net product sales of any QTORIN rapamycin-based products, recorded as a royalty agreement liability of $11.9 million as of December 31, 2025.

Products and services

QTORIN rapamycin: clinical-stage topical candidate for rare skin diseases with orphan designation potential. QTORIN pitavastatin: in IND-enabling development for DSAP (disseminated superficial actinic porokeratosis). No products approved for commercial sale as of the 10-K filed March 31, 2026.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets are patients with rare dermatological conditions. The company plans to build a specialized U.S. commercial organization upon any future marketing approval.

Value-chain role

Clinical-stage drug developer. Relies on third-party contract manufacturers for clinical-stage supply. Plans to establish commercial manufacturing and sales infrastructure only after potential regulatory approval.

Geographic exposure

U.S.-focused development and planned commercialization. EU orphan medicinal product regulations referenced as applicable to potential future market exclusivity, indicating consideration of European markets.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: Axcella Health Inc. GELESIS HOLDINGS, INC. Fortress Biotech Inc Cue Biopharma, Inc. PDS Biotechnology Corp FINCH THERAPEUTICS GROUP, INC. HCW Biologics Inc Longeveron Inc SPECTRUM PHARMACEUTICALS INC